

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12N 15/12, C07K 16/28, 14/475, C12N 15/62, C07K 16/46, A61K 38/18, G01N 33/53, C12N 5/10, 5/12	A1	(11) International Publication Number: WO 96/38557 (43) International Publication Date: 5 December 1996 (05.12.96)
(21) International Application Number: PCT/US96/08094 (22) International Filing Date: 31 May 1996 (31.05.96) (30) Priority Data: 08/460,368 2 June 1995 (02.06.95) US (60) Parent Application or Grant (63) Related by Continuation US 08/460,368 (CIP) Filed on 2 June 1995 (02.06.95) (71) Applicant (for all designated States except US): GENENTECH, INC. [US/US]; 460 Point San Bruno Boulevard, South San Francisco, CA 94080-4990 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SCHWALL, Ralph, H. [US/US]; 400 Griffin Avenue, Pacifica, CA 94044 (US). TABOR, Kelly, Helen [US/US]; 1053 La Cuesta, Hillsborough, CA 94010 (US).	(74) Agents: MARSCHANG, Diane, L. et al.; Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080-4990 (US). (81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: HEPATOCYTE GROWTH FACTOR RECEPTOR ANTAGONISTS AND USES THEREOF		
(57) Abstract <p>Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.</p>		